ANI SVP reports stock grant and tax withholding

ANI Pharmaceuticals SVP Chad Gassert reported equity compensation and related tax withholding transactions in company stock.

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP Chad Gassert reported equity compensation and related tax withholding transactions in company stock. On February 26, 2026, he acquired 11,116 shares of common stock as a restricted stock award at $77.15 per share, scheduled to vest in four equal annual installments on the first through fourth anniversaries of February 26, 2026.

On February 28, 2026, 2,221 shares were withheld at $73.90 per share to cover taxes tied to the vesting of 4,342 previously granted restricted shares, leaving 74,916 shares held directly. He also has indirect ownership of 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Gassert Chad

Role SVP - CORP. DEV. & STRATEGY

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,221	$73.90	$164K
Grant/Award	Common Stock	11,116	$77.15	$858K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 74,916 shares (Direct); Common Stock — 158,490 shares (Indirect, Held by Chali Properties LLC)

Footnotes (3)

1. F1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.
2. F2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.
3. F3. The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ANI Pharmaceuticals (ANIP) SVP Chad Gassert report?

Chad Gassert reported a restricted stock award of 11,116 ANI Pharmaceuticals common shares and a related tax-withholding disposition of 2,221 shares. These transactions reflect equity compensation vesting and associated tax payments, not an open-market purchase or sale of stock.

How many ANI Pharmaceuticals (ANIP) shares did Chad Gassert acquire in the latest Form 4?

He acquired 11,116 shares of ANI Pharmaceuticals common stock as a restricted stock award at $77.15 per share. According to the filing, this award will vest in four equal annual installments starting on February 26, 2027, through the fourth anniversary.

Why were 2,221 ANI Pharmaceuticals (ANIP) shares disposed of in Chad Gassert’s Form 4?

The 2,221 shares were withheld for tax purposes in connection with the vesting of 4,342 restricted shares previously granted. This tax-withholding disposition at $73.90 per share satisfied tax obligations rather than representing an open-market stock sale by Chad Gassert.

What is Chad Gassert’s direct and indirect ANI Pharmaceuticals (ANIP) share ownership after these transactions?

After the reported transactions, Chad Gassert directly holds 74,916 ANI Pharmaceuticals common shares. He also indirectly owns 158,490 shares held by Chali Properties LLC, where the filing states he has both voting and dispositive power over those shares.

How do the new restricted shares for ANI Pharmaceuticals (ANIP) SVP Chad Gassert vest?

The 11,116-share restricted stock award vests in four equal annual installments. Vesting occurs on the first, second, third and fourth anniversaries of February 26, 2026, aligning the equity compensation with multi-year service and performance at ANI Pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 05:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gassert Chad

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP - CORP. DEV. & STRATEGY

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A(1)		11,116	A	$77.15	77,137	D
Common Stock	02/28/2026		F(2)		2,221	D	$73.9	74,916	D
Common Stock								158,490	I	Held by Chali Properties LLC(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

3. The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Remarks:

	/s/ Chad Gassert, by attorney-in-fact Meredith W. Cook	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.